MedTrace Logo

DETECT-IP: a Clinical Decision Support System and Intelligent Procedures to Counter Some Adverse Drug Events in Older Hospital Patients

NCT05923983 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 783

Last updated 2025-12-26

No results posted yet for this study

Summary

Current evidence shows that computerized decision support systems (CDSS) have shown to be insufficiently effective to prevent adverse drug reactions (ADRs) at large scale (e.g. whole hospital). Several barriers for successful implementation of CDSS have been identified: over-alerting, lack of specificity of rules, and physician interruption during prescription. The effectiveness of CDSS could be increased in two ways. Firstly, by creating rules that are more specific to a given adverse drug reaction: the current study focuses on acute renal failure and hyperkalemia (two serious and frequent ADR in older hospitalized patients). Secondly, by involving the pharmacist in the review of the alerts so that he/she can transmit, if deemed necessary, a pharmaceutical recommendation to the clinician. This procedure will reduce over-alerting and prevent task interruption.

The hypothesis is that the use of specific rules created by a multidisciplinary team and implemented in a CDSS, combined with a strategy for managing and transmitting alerts, can reduce specific ADRs such as hyperkalemia and acute renal failure.

Conditions

  • Patient Acceptance of Health Care
  • Acute Renal Failure

Interventions

OTHER

Clinical decision support

In the intervention group, the pharmaceutical validation will be based on routine care, often on entry to a ward and by analysis of all the alerts produced by the CDSS. Some alerts will result in a pharmaceutical intervention being provided to the medical team

OTHER

Will not receive Clinical Decision Support

In the control group, the pharmaceutical validation will be based on routine care, often on entry to a ward or in a particular situation

Sponsors & Collaborators

  • OméDIT (Observatory of Medicines, Medical Devices and Therapeutic Innovations

    collaborator UNKNOWN

  • Regional Agency of Sante Nord Pas-de-Calais

    collaborator OTHER

  • University Hospital, Lille

    lead OTHER

Principal Investigators

  • Jean-Bapstiste Beuscart, MD · University Hospital, Lille

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
SINGLE
Model
SEQUENTIAL

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-02
Primary Completion
2024-10-03
Completion
2024-10-03

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05923983 on ClinicalTrials.gov